File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Human monoclonal antibodies to the S glycoprotein and related proteins as potential therapeutics for SARS

TitleHuman monoclonal antibodies to the S glycoprotein and related proteins as potential therapeutics for SARS
Authors
Issue Date2005
PublisherCurrent Drugs Ltd. The Journal's web site is located at http://www.biomedcentral.com/1464-8431
Citation
Current Opinion In Molecular Therapeutics, 2005, v. 7 n. 2, p. 151-156 How to Cite?
AbstractPolyclonal antibodies have a century-old history of being effective against some viruses and, recently, monoclonal antibodies (mAbs) have also shown some clinical success. Human mAbs to the severe acute respiratory syndrome (SARS) coronavirus spike glycoprotein have been developed by several research groups at an amazing pace. These antibodies potently neutralize infectious virus in tissue cultures and animal models, and, alone or in combination with vaccines and other drugs, may have potential for the prevention and treatment of SARS. © The Thomson Corporation.
Persistent Identifierhttp://hdl.handle.net/10722/157402
ISSN
2012 Impact Factor: 3.416
2013 SCImago Journal Rankings: 1.196
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorZhang, MYen_US
dc.contributor.authorChoudhry, Ven_US
dc.contributor.authorXiao, Xen_US
dc.contributor.authorDimitrov, DSen_US
dc.date.accessioned2012-08-08T08:49:40Z-
dc.date.available2012-08-08T08:49:40Z-
dc.date.issued2005en_US
dc.identifier.citationCurrent Opinion In Molecular Therapeutics, 2005, v. 7 n. 2, p. 151-156en_US
dc.identifier.issn1464-8431en_US
dc.identifier.urihttp://hdl.handle.net/10722/157402-
dc.description.abstractPolyclonal antibodies have a century-old history of being effective against some viruses and, recently, monoclonal antibodies (mAbs) have also shown some clinical success. Human mAbs to the severe acute respiratory syndrome (SARS) coronavirus spike glycoprotein have been developed by several research groups at an amazing pace. These antibodies potently neutralize infectious virus in tissue cultures and animal models, and, alone or in combination with vaccines and other drugs, may have potential for the prevention and treatment of SARS. © The Thomson Corporation.en_US
dc.languageengen_US
dc.publisherCurrent Drugs Ltd. The Journal's web site is located at http://www.biomedcentral.com/1464-8431en_US
dc.relation.ispartofCurrent Opinion in Molecular Therapeuticsen_US
dc.subject.meshAnimalsen_US
dc.subject.meshAntibodies, Monoclonal - Immunology - Therapeutic Useen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunoglobulins - Genetics - Immunologyen_US
dc.subject.meshMiceen_US
dc.subject.meshMice, Transgenicen_US
dc.subject.meshSars Virus - Immunologyen_US
dc.subject.meshSevere Acute Respiratory Syndrome - Drug Therapy - Immunologyen_US
dc.subject.meshViral Proteins - Immunologyen_US
dc.titleHuman monoclonal antibodies to the S glycoprotein and related proteins as potential therapeutics for SARSen_US
dc.typeArticleen_US
dc.identifier.emailZhang, MY:zhangmy@hku.hken_US
dc.identifier.authorityZhang, MY=rp01409en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid15844623-
dc.identifier.scopuseid_2-s2.0-17144382020en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-17144382020&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume7en_US
dc.identifier.issue2en_US
dc.identifier.spage151en_US
dc.identifier.epage156en_US
dc.identifier.isiWOS:000228420800009-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridZhang, MY=35316639300en_US
dc.identifier.scopusauthoridChoudhry, V=8530897500en_US
dc.identifier.scopusauthoridXiao, X=7402168892en_US
dc.identifier.scopusauthoridDimitrov, DS=7202564539en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats